A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

BACKGROUND: We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS: Patients were randomly assigned in a 1:1:1:1 ratio to one of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Chemother Pharmacol
Asıl Yazarlar: Ueno, Makoto, Li, Chung Pin, Ikeda, Masafumi, Ishii, Hiroshi, Mizuno, Nobumasa, Yamaguchi, Taketo, Ioka, Tatsuya, Oh, Do Youn, Ichikawa, Wataru, Okusaka, Takuji, Matsuyama, Yutaka, Arai, Daichi, Chen, Li Tzong, Park, Young Suk, Furuse, Junji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532401/
https://ncbi.nlm.nih.gov/pubmed/28634650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3351-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller